OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO) London and New Yo

Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of

the Association for Research in Vision and Ophthalmology (ARVO)

and New York, NY, April 30, 2024 - OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative

ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment

diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, today

announced an upcoming presentation of the OK-101 Phase 2 data for dry eye disease at the Dry Horizons Symposium, a partner meeting of

the Association for Research in Vision and Ophthalmology (ARVO), being held May 3, 2024 in Seattle, WA.

Friday May 3, 2024, 2:50-3:45 PM PST

Four Seasons Seattle, WA

Gary Jacob, PhD, Chief Executive Officer

Dry Horizons Symposium

clinical leaders and industry innovators to tackle significant challenges in the dry eye market. With the rising prevalence of dry eye

disease, the shortcomings of existing treatments, as well as new opportunities for advancing clinical pathways based on recent successful

therapies, this symposium will provide in-depth coverage of the global landscape of Dry Eye and the opportunity for further innovation.

From the impact of technology use on eye health, to unexplored therapeutics, to accelerating research and development, this new event

will showcase the urgent need for innovative clinical solutions to benefit current and future patients.

Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED

and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel

molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway

for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition. For further information, please

visit www.okyopharma.com.